Low dose thalidomide combined with VAD regimen contained one-week dexamethasone on 42 cases of patients with multiple myeloma
10.3760/cma.j.issn.1006-9801.2011.07.014
- VernacularTitle:小剂量沙利度胺联合含单周地塞米松的VAD方案治疗多发性骨髓瘤42例
- Author:
Yanjun WANG
;
Jie WU
;
Qing DONG
;
Ting WANG
;
Xueyong ZHANG
- Publication Type:Journal Article
- Keywords:
Multiple myeloma;
Drug therapy;
combination;
Therapy
- From:
Cancer Research and Clinic
2011;23(7):479-482
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and toxicity of low dose thalidomide combined with VAD regimen contained one-week dexamethasone in treatment on patients with multiple myeloma (MM). Methods 42 patients with MM were diagnosed in our hospital.The VAD regimen contained one-week dexamethasone was vincristine 0.4 mg/d, adramycin 10 mg/d and dexamethasone 40 mg/d for 4 days. At the same time, thalidomide is given 150-200 mg/d. Results The overall response rate (ORR) is 80.95%. Before and after treatment, all the detection indicators in MM patients were statistically different (P＜0.001). There is small adverse reactions. Conclusion Low dose thalidomide combined with VAD regimen contained one-week dexamethasone in treatment of MM has more merits such as less side effects, good tolerance, convenient administration and significant curative effects, so it should be recommended in clinical works.
